everolimus sold brand name afinitor among others medication used immunosuppressant prevent rejection organ targeted therapy treatment renal cell cancer compound also use cardiovascular drugeluting stent technologies inhibit restenosis derivative sirolimus works similarly sirolimus inhibitor mammalian target rapamycin marketed novartis trade names zortress us certican european union countries transplantation medicine afinitor general tumours votubia tumours result tuberous sclerosis complex tsc oncologycitation needed world health organizations list essential available generic everolimus approved various conditions nhs england criticised delays deciding policy prescription everolimus treatment tuberous sclerosis doctors addressed letter board support charity tuberous sclerosis association saying around patients critical need whose doctors believe everolimus treatment best option hope access funding waiting many months approximately half patients imminent risk catastrophic event renal bleed kidney failure high risk preventable may reported luke henry stephanie rudwick parents child suffering tuberous sclerosis trying sell home brighton raise pay treatment daughter bethany tumours brain kidneys liver suffers epileptic fits october phase iii trials way gastric cancer hepatocellular carcinoma experimental use everolimus refractory chronic graftversushost disease reported interim phase iii trial results showed adding afinitor everolimus exemestane therapy advanced breast cancer significantly improve progressionfree survival compared exemestane therapy study published shows everolimus sensitivity varies patients depending tumor group patients advanced metastasic bladder carcinoma treated everolimus revealed single patient complete response everolimus treatment months researchers sequenced genome patient compared different reference genomes patients genomes found mutations led lengthened duration response everolimus increase time cancer recurrence mutated apparently made tumors vulnerable treatment everolimusmedical citation needed phase iia randomized placebocontrolled everolimus clinical trial published showed everolimus improved response influenza vaccine healthy elderly phase iia randomized placebocontrolled clinical trial published showed everolimus combination dactolisib decreased rate reported infections elderly compared parent compound rapamycin everolimus compared rapamycin everolimus selective protein complex little impact lead hyperactivation kinase akt via inhibition negative feedback loop inhibiting positive feedback akt akt elevation lead longer survival cell typesmedical citation needed thus everolimus important effects cell growth cell proliferation cell survival inhibition everolimus shown normalize tumor blood vessels increase tumorinfiltrating lymphocytes improve adoptive cell transfer additionally believed play important role glucose metabolism immune system suggesting selective inhibition drugs everolimus could achieve many benefits rapamycin without associated glucose intolerance genes involved tuberous sclerosis act tumor suppressor genes regulating activity thus either loss inactivation one genes lead activation everolimus binds protein receptor directly interacts inhibiting downstream signaling consequence mrnas code proteins implicated cell cycle glycolysis process impaired altered tumor growth trial using mgday patients nets gi lung origin reported everolimus discontinued adverse reactions patients dose reduction delay required everolimustreated patients serious adverse reactions occurred everolimustreated patients included fatal events cardiac failure respiratory failure septic shock common adverse reactions incidence greater equal stomatitis infections diarrhea peripheral edema fatigue rash common blood abnormalities found incidence greater equal anemia hypercholesterolemia lymphopenia elevated aspartate transaminase ast fasting everolimus may role heart transplantation shown reduce chronic allograft vasculopathy transplants also may similar role sirolimus kidney although sirolimus generated fears use mtor inhibitors liver transplantation recipients due possible early hepatic artery thrombosis graft loss use everolimus setting liver transplantation promising jeng et study patients concluded safety everolimus early phase living donor liver transplantation study hepatic artery thrombosis wound infection noted also possible role everolimus reducing recurrence hepatocellular carcinoma liver transplantation correlated target trough level ngml months shown beneficial recipients pretransplant renal dysfunction study renal failure patients showed significant recovery renal function whereas showed deterioration one required positive impact hepatocellular carcinoma hcc observed everolimus used primary immunosuppression starting early first week living donor liver transplantation ldlt everolimus used drugeluting coronary stents immunosuppressant prevent restenosis abbott vascular produce everolimuseluting stent ees called xience alpine utilizes multilink vision cobalt chromium stent platform novartis everolimus product widely available globally including us european union asiapacific apac countries boston scientific also market eeses recent offerings promus elite synergycitation needed inhibition mtor molecular target everolimus extends lifespan model organisms including mtor inhibition suggested antiaging therapy everolimus used clinical trial novartis shortterm treatment shown enhance response influenza vaccine elderly possible reversing everolimus treatment mice results reduced metabolic side effects compared httpsenwikipediaorgwikieverolimus